about
Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza.Pharmacodynamics of empirical antibiotic monotherapies for an intensive care unit (ICU) population based on Canadian surveillance data.Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus.Evaluating ciprofloxacin dosing for Pseudomonas aeruginosa infection by using clinical outcome-based Monte Carlo simulations.New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.Antibiotic pharmacodynamics in surgical prophylaxis: an association between intraoperative antibiotic concentrations and efficacy.Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin.Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination.Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent.Aminoglycoside-induced vestibular injury: maintaining a sense of balance.Peritoneal fluid titer test for peritoneal dialysis-related peritonitis.Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia.Optimization of meropenem dosage in the critically ill population based on renal function.Successful treatment of pulmonary blastomycosis with continuously infused amphotericin B deoxycholate after failure with liposomal amphotericin B.Multifaceted antibiotic treatment analysis of methicillin-sensitive Staphylococcus aureus bloodstream infections.An evaluation of an optimal sampling strategy for meropenem in febrile neutropenics.Microbiological Trends and Antimicrobial Resistance in Peritoneal Dialysis-Related Peritonitis, 2005 to 2014.Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia.Bayesian pharmacokinetic analysis of a gentamicin nomogram in neonates: a retrospective studyTargeted benefits of prolonged-infusion piperacillin-tazobactam in an in vitro infection model of Pseudomonas aeruginosa.In vitro antifungal activity of BMS-181184 against systemic isolates of Candida, Cryptococcus, and Blastomyces species.Preferential emergence of reduced vancomycin susceptibility in health care-associated methicillin-resistant Staphylococcus aureus isolates during continuous-infusion vancomycin therapy in an in vitro dynamic model.Support for higher ciprofloxacin AUC 24/MIC targets in treating Enterobacteriaceae bloodstream infection.Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia.Simulation of cyclic reprocessing buildup on reused medical devices.AUC(0-t)/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model.A reevaluation of empiric therapy for peritoneal dialysis-related peritonitis.Vancomycin pharmacodynamics and survival in patients with methicillin-resistant Staphylococcus aureus-associated septic shock.Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis.Effect of antibiotic sequence on combination regimens against Pseudomonas aeruginosa in a multiple-dose, in vitro infection model.Antibiotic combinations significantly more active than monotherapy in an in vitro infection model of Stenotrophomonas maltophilia.Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.Effectiveness of a 30% ethanol/4% trisodium citrate locking solution in preventing biofilm formation by organisms causing haemodialysis catheter-related infections.Effect of an ethanol/trisodium citrate hemodialysis catheter locking solution on isolates of Candida albicans.Adequacy of a vancomycin dosing regimen in patients receiving high-flux hemodialysis.No role for patient body weight on renal function assessment for drug dosing.Evaluation of cefazolin antimicrobial prophylaxis during cardiac surgery with cardiopulmonary bypass.Correction to: Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
P50
Q30385708-F12DD61B-50BB-4C43-BBCE-42096682680BQ33711696-021737F0-B3A7-4B63-B6C5-F20E31DA6C4CQ34017518-67AE5F3D-BB0E-4CC7-8F56-4EC92AF8A1CAQ34077003-A673877C-45FD-4EB7-B412-AFFCFF73FDB5Q34112687-7566E7BB-F24E-45EF-B4EF-8616F531F2E3Q34112924-D78DAE5A-CB8B-4A98-9CBE-1AED5118D620Q34269044-8A4FCE16-9BAC-4074-A15C-3307F91733D2Q34325573-23572967-63AF-40F6-980A-69296C4CFD94Q34393008-EC80FEBF-7063-4B5F-BC1E-3E6680E93DF3Q34513298-2DA57777-70F7-43B2-BD2D-C03ABC012C6BQ37224123-5AD1C7CB-FA68-416E-84CD-32620FE2BF9FQ37734670-1E21FC57-9589-401D-9CFC-6C35692278FEQ38352171-5F640621-40BE-41DF-9597-212A90993022Q39026738-888FFFE0-F2E4-4745-8E71-0AA5E831932AQ39961839-9E0ED6E8-CB5E-42E5-B5AE-279C4B01EC92Q40247785-DFE5F0F2-650D-400B-B6BA-70D023639757Q40478950-07A6A7DE-CEF0-4D37-B476-AD38F76329D6Q40506427-25208CE3-FC48-44AA-9F6A-FC8F8D3CFFBDQ40507755-27333B20-7031-441D-8C29-6298BFE33603Q40519156-2E66C969-C31D-4117-80F0-15B4C11C18F1Q40561487-2633A143-7D91-40F0-8AE5-D5C01CC5A486Q40714798-795B1BC7-D6F6-4434-BA63-EFEF7728D2C6Q42547225-574C16F1-3BA6-48E7-B0C0-9E9C1340B8A0Q42772417-447B32C8-B6D7-456B-8270-75F311F1BC01Q43014218-F2A2B9EC-1922-4D6A-8663-71386D405542Q43153489-B760539C-FEC8-46B5-8BAD-81A4738AAD38Q43626676-F83EEEB6-F7CB-4934-B8BC-2C67AC5E33C0Q43682500-8DE79CFF-5A7E-442B-82AF-4D52C6BC91EAQ44108763-9DA59382-FEA8-4E9A-AEF0-EBC11D01AFBFQ44374093-7DBE34E5-9D50-4530-9195-A20836FF1A3DQ44570722-72E52C45-CB50-486D-AD43-92F915074BEBQ44890379-3A30500E-266F-41F2-A8CC-32E52508C3A5Q45209301-0DAFA513-BDD1-4FFF-A0E5-557870DA4FC8Q46243175-78BC6DFA-A0F1-47D0-A1C1-BFFFE9C6910EQ46473346-67DC4B01-3A00-494B-8945-B4369885FFC7Q46475502-E07188F8-7659-46AB-B887-F526038F0E21Q46720261-D5DC992D-6466-4F7B-99FF-F4DC681C5E4AQ47223964-2150E3D5-1A96-40B5-B110-6C69CB4FCFCCQ47297439-CFD52F66-D4CA-4B3D-B3C2-12DB3F8D0F39Q54214900-F9028138-C803-4B7D-A097-DE8A1FA51513
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Sheryl A. Zelenitsky
@ast
Sheryl A. Zelenitsky
@en
Sheryl A. Zelenitsky
@es
Sheryl A. Zelenitsky
@sl
type
label
Sheryl A. Zelenitsky
@ast
Sheryl A. Zelenitsky
@en
Sheryl A. Zelenitsky
@es
Sheryl A. Zelenitsky
@sl
prefLabel
Sheryl A. Zelenitsky
@ast
Sheryl A. Zelenitsky
@en
Sheryl A. Zelenitsky
@es
Sheryl A. Zelenitsky
@sl
P106
P1153
7004200473
P21
P31
P496
0000-0003-1891-1999